SynthesisThoracic cancer2019
Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: A comprehensive systematic review and meta-analysis.
Synthesis in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prediabetes and the risk of lung cancer incidence and mortality: A meta-analysis.Journal of diabetes investigation · 2023Pooled it
- Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysis.BMC cancer · 2022Pooled it
- The Effect of Diabetes Mellitus on Prognosis of Patients with Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2020Pooled it
- Diabetes and cancer: glucose control impact on survival and tumor outcomes.Reviews in endocrine & metabolic disorders · 2026Review
- Management of wound dehiscence with negative pressure in diabetic patients undergoing pulmonary resection for lung cancer.Frontiers in surgery · 2026Article
- Targeting the molecular crosstalk between diabetes and lung cancer for therapeutic intervention.Discover oncology · 2025Review
- Streptozotocin-induced hyperglycemia unmasks cardiotoxicity induced by doxorubicin.Scientific reports · 2025Article
- Glycemic management in patients with immune-related diabetes mellitus: A scoping review.SAGE open medicine · 2025Review
- Metabolomic Profiling of Tumor Tissues Unveils Metabolic Shifts in Non-Small Cell Lung Cancer Patients with Concurrent Diabetes Mellitus.Journal of proteome research · 2024Article
- Glycemic control in diabetic patients improved overall lung cancer survival across diverse populations.JNCI cancer spectrum · 2024Article
- Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential.Frontiers in pharmacology · 2024Review
- Impact of diabetes on stage I lung cancer treatment patterns and prognosis in older adults: A population-based cohort study.Heliyon · 2023Article
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival.British journal of cancer · 2023Article
- Impact of Type 2 Diabetes Mellitus on the Prognosis of Non-Small Cell Lung Cancer.Journal of clinical medicine · 2022Article
- Multiple factors affecting perioperative antibiotherapy in minimally invasive lung surgery: a retrospective case-control study.Journal of thoracic disease · 2022Article
- Impact of Diabetes on Short-Term and Long-Term Outcomes of Ampullary Adenocarcinoma Patients after Curative Pancreatoduodenectomy.Current oncology (Toronto, Ont.) · 2022Article
- Changes in target ability of nanoparticles due to protein corona composition and disease state.Asian journal of pharmaceutical sciences · 2022Article
- The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus.Frontiers in oncology · 2021Article
- PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study.Journal of Cancer · 2021Article
- [Research Advance in Anti-lung Cancer Mechanism of Metformin].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) is one of the most common comorbidities in surgically treated non-small cell lung cancer (NSCLC) patients and has a negative impact on short-term outcomes. However, the impact of DM on long-term survival of such patients remains controversial; therefore, we conducted a comprehensive updated meta-analysis.
methodsWe systematically searched relevant studies in PubMed, Embase, Cochrane Library, and Web of Science up to 6 September 2018. Hazard ratios (HRs) for the impact of DM on overall survival (OS) and recurrence-free survival (RFS) of patients with surgically treated NSCLC were extracted and analyzed using the STATA 12.0 package.
resultsWe included 13 cohort studies consisting of 4343 patients (730 patients with DM and 3613 patients without) with surgically treated NSCLC. Meta-analysis showed that patients with DM had significantly poorer OS (random effects: HR 1.30, 95% confidence interval 1.05-1.60; P = 0.016) than those without. However, with a limited sample size, there was no significant difference in RFS (random effects: HR 1.06, 95% confidence interval 0.71-1.58; P = 0.786) between patients with and without DM after surgical resection of NSCLC.
conclusionDM is an independent unfavorable prognostic factor for patients with surgically treated NSCLC. High-quality studies with appropriate adjustment for confounding factors are needed to confirm our conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.